Enzon (ENZN) Reports Positive Preliminary Data in Company’s HIF-1 Alpha Phase 1 Study Evaluating EZN-2968 in Patients With Solid Tumors
Tweet Send to a Friend
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced that data from the Company’s HIF-1 alpha Phase 1 study evaluating EZN-2968 in patients ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
